|
|
 Previous Article | Table of Contents | Next Article 
Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets
by human complement and cytokinine-exposed mononuclear and neutrophilic
polymorphonuclear leukocytes
L Ottonello, P Morone, P Dapino and F Dallegri
First Medical Clinic, Department of Internal Medicine, University of
Genova, Genova, Italy.
Lym-1 is a murine IgG2a monoclonal antibody that recognizes a polymorphic
variant of HLA-DR antigens on malignant B cells, with minimal
cross-reactivity with normal tissues. Because it can be safely administered
in vivo, a detailed knowledge of its ability to recruit and trigger the
antitumor immune effector systems is required to optimize potential
serotherapeutic approaches in B-lymphoma patients. By using Raji cells as a
model of B-lymphoma targets, we found that Lym- 1 activates
complement-mediated lysis efficiently. Moreover, Lym-1 was capable of
triggering the antibody-dependent cellular cytolysis (ADCC) by peripheral
blood mononuclear cells (MNCs). On the contrary, it failed to trigger
neutrophilic polymorphonuclear leukocyte (PMN)- mediated ADCC activity. In
an attempt to enhance Lym-1 ADCC by MNCs and PMNs, nine biologic response
modifiers were tested. MNC-mediated Lym-1 ADCC was significantly stimulated
by interleukin-2 (IL-2) and unaffected by other mediators, including
gamma-interferon (gamma-IFN), tumor necrosis factor a (TNFalpha), and
granulocyte-macrophage colony- stimulating factor (GM-CSF). On the other
hand, PMN-mediated Lym-1 ADCC was induced or significantly augmented by
various cytokines, such as GM- CSF, TNFalpha, and gamma-IFN, and
chemotaxins, such as formyl peptides (FMLP), complement fragment C5a, and
IL-8. Both MNC- and PMN-mediated ADCC was unaffected by granulocyte
colony-stimulating factor (G- CSF) and insulin-like growth factor-1
(IGF-1). Finally, only GM-CSF and TNFalpha augmented the number of PMNs
actually engaged in the binding of Raji target cells. The findings
presented here, in particular those showing stimulatory activity of
biologic response modifiers, may inspire new attempts for developing Lym-1
antibody-based approaches to the therapy of B lymphomas.
Volume 87,
Issue 12,
pp. 5171-5178,
06/15/1996
Copyright © 1996 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. S. Czuczman, S. Olejniczak, A. Gowda, A. Kotowski, A. Binder, H. Kaur, J. Knight, P. Starostik, J. Deans, and F. J. Hernandez-Ilizaliturri
Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels
Clin. Cancer Res.,
March 1, 2008;
14(5):
1561 - 1570.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Horner, C. Frank, C. Dechant, R. Repp, M. Glennie, M. Herrmann, and B. Stockmeyer
Intimate Cell Conjugate Formation and Exchange of Membrane Lipids Precede Apoptosis Induction in Target Cells during Antibody-Dependent, Granulocyte-Mediated Cytotoxicity
J. Immunol.,
July 1, 2007;
179(1):
337 - 345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Duan, L. Remeijer, J. M. van Dun, A. D. M. E. Osterhaus, and G. M. G. M. Verjans
Granulocyte Macrophage Colony-Stimulating Factor Expression in Human Herpetic Stromal Keratitis: Implications for the Role of Neutrophils in HSK
Invest. Ophthalmol. Vis. Sci.,
January 1, 2007;
48(1):
277 - 284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-Y. Xiong, A. Natarajan, X.-B. Shi, G. L. Denardo, and S. J. Denardo
Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding
Protein Eng. Des. Sel.,
August 1, 2006;
19(8):
359 - 367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N.-K. V. Cheung, R. Sowers, A. J. Vickers, I. Y. Cheung, B. H. Kushner, and R. Gorlick
FCGR2A Polymorphism Is Correlated With Clinical Outcome After Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor
J. Clin. Oncol.,
June 20, 2006;
24(18):
2885 - 2890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Wagner, C. Iking-Konert, B. Denefleh, S. Stegmaier, F. Hug, and G. M. Hansch
Granzyme B and perforin: constitutive expression in human polymorphonuclear neutrophils
Blood,
February 1, 2004;
103(3):
1099 - 1104.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ottonello, A. L. Epstein, M. Mancini, P. Dapino, and F. Dallegri
Monoclonal LYM-1 antibody-dependent cytolysis by human neutrophils exposed to GM-CSF: auto-regulation of target cell attack by cathepsin G
J. Leukoc. Biol.,
January 1, 2004;
75(1):
99 - 105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Stockmeyer, T. Beyer, W. Neuhuber, R. Repp, J. R. Kalden, T. Valerius, and M. Herrmann
Polymorphonuclear Granulocytes Induce Antibody-Dependent Apoptosis in Human Breast Cancer Cells
J. Immunol.,
November 15, 2003;
171(10):
5124 - 5129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Dechant, G. Vidarsson, B. Stockmeyer, R. Repp, M. J. Glennie, M. Gramatzki, J. G. J. van de Winkel, and T. Valerius
Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing
Blood,
December 15, 2002;
100(13):
4574 - 4580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Juweid
Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice
J. Nucl. Med.,
November 1, 2002;
43(11):
1507 - 1529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ottonello, A. L. Epstein, M. Mancini, M. Amelotti, P. Dapino, and F. Dallegri
Monoclonal Lym-1 antibody-targeted lysis of B lymphoma cells by neutrophils. Evidence for two mechanisms of Fc{gamma}RII-dependent cytolysis
J. Leukoc. Biol.,
November 1, 2000;
68(5):
662 - 668.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L. Ottonello, A.L. Epstein, P. Dapino, P. Barbera, P. Morone, and F. Dallegri
Monoclonal Lym-1 Antibody-Dependent Cytolysis by Neutrophils Exposed to Granulocyte-Macrophage Colony-Stimulating Factor: Intervention of Fc{gamma}RII (CD32), CD11b-CD18 Integrins, and CD66b Glycoproteins
Blood,
May 15, 1999;
93(10):
3505 - 3511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ottonello, G. Tortolina, M. Amelotti, and F. Dallegri
Soluble Fas Ligand Is Chemotactic for Human Neutrophilic Polymorphonuclear Leukocytes
J. Immunol.,
March 15, 1999;
162(6):
3601 - 3606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Hornick, L. A. Khawli, P. Hu, M. Lynch, P. M. Anderson, and A. L. Epstein
Chimeric CLL-1 Antibody Fusion Proteins Containing Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-2 With Specificity for B-Cell Malignancies Exhibit Enhanced Effector Functions While Retaining Tumor Targeting Properties
Blood,
June 15, 1997;
89(12):
4437 - 4447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
